Archives

Pipeline

New Pipeline Updates from Inhibrx Inc., OBI Pharma and ApiFix Ltd.

September 8, 2019

Company Drug/Device Medical Condition Status
Inhibrx Inc. INBRX-101 alpha-1 antitrypsin deficiency (AATD) Phase 1 trial initiated
Ribon Therapeutics RBN-2397 cancer Phase 1 trial initiated enrolling 2,397 subjects with various tumor types, including squamous cell carcinoma of the lung

Infinity Pharmaceuticals

Arcus Biosciences

IPI-549 in combination with Arcus’ AB298 and Doxil advanced triple negative breast cancer (TNBC) Phase 1/1b trial initiated
Hutchison China MediTech Limited HMPL-689 relapsed or refractory lymphoma Phase 1/1b trial initiated
Rocket Pharmaceuticals, Inc. RP-L201 severe Leukocyte Adhesion Deficiency-I (LAD-I) Phase 1/2 trial initiated enrolling nine pediatric subjects globally

Infinity Pharmaceuticals

Genentech

IPI-549 in combination with Tecentriq and Abraxane (nab-paclitaxel) front-line triple negative breast cancer (TNBC) Phase 2 trial initiated
OBI Pharma OBI-999 Globo H IND approval granted by the FDA
Magenta Therapeutics MGTA-456 metabolic disorders RMAT designation granted by the FDA
Prescient Metabiomics LifeKit Prevent Colorectal Neoplasia Test colorectal cancer (CRC) Breakthrough Device designation granted by the FDA
Ra Pharmaceuticals, Inc. zilucoplan myasthenia gravis Orphan Drug designation granted by the FDA
ApiFix Ltd. Minimally Invasive Deformity Correction (MID-C) system progressive adolescent idiopathic scoliosis (AIS) HDE approval granted by the FDA
US WorldMeds, LLC MYOBLOC (rimabotulinumtoxinB) injection chronic sialorrhea sBLA approval granted by the FDA